Abstracts tagged "Inflammation"

Abstract Number: 0619 • ACR Convergence 2022
Differences Between Patients in Remission with Active Rheumatoid Arthritis by Histological and Molecular Comparisons
Selina Ohl¹, Klaus Frommer², Markus Rickert³, Stefan Rehart⁴, Ulf Müller-Ladner⁵ and Elena Neumann⁶, ¹Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, ²Justus Liebig University Gießen, Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, ³Dept. of Orthopaedics and Orthopaedic Surgery, University Hospital Giessen and Marburg, Giessen, Germany, Gießen, Germany, ⁴Agaplesion Markus Hospital, Dpt of Orthopaedics and Trauma Surgery, Frankfurt, Germany, ⁵JLU Campus KK, Bad Nauheim, Germany, ⁶JLU Gießen, Campus Kerckhoff, Bad Nauheim, Germany
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease, whose inflammatory processes in the synovium lead to the destruction of cartilage and bone. Although there…
Abstract Number: 1107 • ACR Convergence 2022
Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): A Prospective Study
Xinlei Ma, Fan Yang, Jin Lin and Weiqian Chen, Division of Rheumatology, the First Affiliated Hospital, Zhejiang University School of Medicine, HangZhou, China
Background/Purpose: Polymyalgia Rheumatica (PMR) is a common inflammatory disease in elderly persons whose pathogenesis is unclear. Glucocorticoids are the first-line drugs for patients with PMR,…
Abstract Number: 1548 • ACR Convergence 2022
Immune Cells Are Highly Disturbed in Polymyalgia Rheumatica Patients
Guillermo CARVAJAL ALEGRIA¹, Sara Boukhlal², Sophie Hillion³, Pierre Pochard³, Emmanuelle Porchet³, Alain Saraux⁴, sandrine jousse joulin⁵, Thierry MARHADOUR⁶, Dewi Guellec³, Divi CORNEC⁷ and Valerie Devauchelle², ¹CHRU de Tours, Tours, France, ²Université de Bretagne Occidentale, Brest, France, ³CHRU de Brest, Brest, France, ⁴CHU Brest, Brest, France, ⁵Roche, Brest, France, ⁶CHU Cavale Blanche, Brest, France, ⁷CHRU Brest, Brest, France
Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory disease. But it's pathophysiology and the impact of the treatments on immune cells are poorly known. Our objectives…
Abstract Number: 1803 • ACR Convergence 2022
Neutrophil-to-lymphocyte Ratio Among Flaring and Non-flaring Uncontrolled Gout Patients Undergoing Pegloticase Therapy as Part of the Phase 3 Pivotal Trials
Michael Pillinger¹, Katie Obermeyer², Lissa Padnick-Silver² and Brian LaMoreaux², ¹NYU Grossman School of Medicine, New York, NY, ²Horizon Therapeutics plc, Deerfield, IL
Background/Purpose: Gout flares result from an innate immune response against monosodium urate crystal deposits, resulting in macrophage crystal phagocytosis and cellular activation.1 NLRP3 inflammasome activation…
Abstract Number: 2027 • ACR Convergence 2022
Labial and Parotid Salivary Gland Histopathology in Primary Sjögren’s Syndrome
Uzma Nakshbandi¹, Martha S. van Ginkel¹, Silvia Liefers², Hendrika Bootsma², Fred Spijkervet², Arjan Vissink¹, Bert van der Vegt¹ and Frans Kroese², ¹University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Salivary gland involvement is a hallmark of disease in primary Sjögren's syndrome (pSS). This is reflected by the prominent role of a positive biopsy…
Abstract Number: 0054 • ACR Convergence 2022
MDSCs in Inflammatory Joints of SKG Mice Suppress T Cells and Differentiate into Osteoclasts
Yoshikazu Fujikawa¹, Sho Sendo², Takumi Nagamoto³, Yuzuru Yamamoto¹, Takaichi Okano⁴, Keisuke Nishimura³, Yo Ueda⁵ and Jun Saegusa⁵, ¹Hyogo Prefectural Harima-Himeji General Medical Center, Himeji, Japan, ²University California, San Diego (UCSD), La Jolla, CA, ³Kobe University, Kobe, Japan, ⁴Kobe University Hospital, Kobe, Japan, ⁵Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Myeloid-derived suppressor cells (MDSCs) are heterogeneous immature myeloid cells with suppressive functions. It is known that MDSCs are expanded in inflammatory sites after migrating…
Abstract Number: 0547 • ACR Convergence 2022
Profiling of Systemic Immune Responses in Axial Spondyloarthritis Patients Reveals Strikingly Distinct Cellular and Molecular Mechanisms of Action of IL-17A Inhibitors and TNF-Blockers
Nicolas Rosine¹, Surya Koturan¹, Vincent Guillemot², Claire Leloup¹, Fanni Veress¹, Tharshana Stephen¹, Hanan Yahia-Cherbal¹, Jérémie SELLAM³, Francis Berenbaum⁴, Natalia Pietrosemoli¹, Elisabetta Bianchi¹, Corinne MIceli⁵ and Lars Rogge¹, ¹Institut Pasteur, Paris, France, ²Institut Pasteur, Paris, Ile-de-France, France, ³Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France, ⁴Sorbonne University - Saint-Antoine hospital, Paris, France, ⁵APHP, Paris, France
Background/Purpose: IL-17A inhibitors (IL-17i) and TNF-inhibitors (TNFi) are currently the only biologic drugs available to treat axial spondyloarthritis (axSpA). While several studies have provided mechanistic…
Abstract Number: 0633 • ACR Convergence 2022
Identification of Systemic Lupus Erythematosus Endotypes by Analysis of Inflammatory and Immunologic Gene Expression Signatures
Erika Hubbard¹, Prathyusha Bachali², Kathryn Kingsmore Allison¹, Yisha He¹, Michelle Catalina³, Amrie Grammer⁴ and Peter Lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²AMPEL BioSolutions, Redmond, WA, ³AMPEL BioSolutions, Harvard, MA, ⁴AMPEL LLC, Charlottesville, VA
Background/Purpose: One of the hallmarks of SLE is clinical and molecular heterogeneity. Recent work has leveraged next-generation sequencing techniques to identify molecular signatures characteristic of…
Abstract Number: 1118 • ACR Convergence 2022
Monocyte Transcriptomic Analysis Uncovers Heterogeneous Gene Expression Profiles in Systemic Lupus Erythematous (SLE) with and Without Subclinical Atherosclerosis
Laurel Woodridge¹, Elvira Chocano Navarro², George Robinson¹, Paul Ashford¹, Kirsty Waddington³, Anisur Rahman⁴, Christine Orengo⁵, Ines Pineda-Torra⁶ and Elizabeth Jury¹, ¹University College London, London, United Kingdom, ²VIHR, Barcelona, Spain, ³University College London (alumni), London, United Kingdom, ⁴Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁵ISMB / UCL, London, United Kingdom, ⁶Cabimer, Sevilla, Spain
Background/Purpose: A leading cause of mortality in SLE is cardiovascular disease (CVD) through accelerated atherosclerosis: the build-up of cells and lipids in the vascular wall.…
Abstract Number: 1608 • ACR Convergence 2022
Vascular Effect of Treat to Target in Early Rheumatoid Arthritis Patients – A 5-year Prospective Study
Huan Meng¹, Isaac Cheng², Byran P Yan¹, Alex PW Lee¹, Ho So¹ and Lai-shan Tam², ¹The Faculty of Medicine, CUHK, Hong Kong, Hong Kong, ²The Chinese University of Hong Kong, Hong Kong, China
Background/Purpose: Rheumatoid arthritis (RA) is associated with accelerated atherosclerosis driven by chronic inflammation. We have previously reported that achieving sustained disease activity score 28 (DAS28)…
Abstract Number: 1832 • ACR Convergence 2022
Efficacy and Safety Similarity of Biosimilar Adalimumab-aqvh to Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Phase III Study
Barbara Finck, Helen Tang, Kathy Jensen, Francesca Civoli and Suzanna Tatarewicz, Coherus BioSciences, Redwood City, CA
Background/Purpose: This study aimed to demonstrate that there were no clinically meaningful differences between adalimumab-aqvh, a US Food and Drug Administration–approved biosimilar, and adalimumab in…
Abstract Number: 2126 • ACR Convergence 2022
Impact of Risankizumab on Enthesitis and Dactylitis: Integrated Analysis of the Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2 Trials
Shawn Kwatra¹, Saakshi Khattri², Ahmad Amin³, Huzefa Photowala⁴, Ran Liu⁴, Byron Padilla⁵, Blair Kaplan⁴ and Dennis McGonagle⁶, ¹John Hopkins University, Baltimore, MD, ²Mount Sinai Medical Center, New York, NY, ³Northwestern Medicine Dermatology, Chicago, IL, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie, Inc., Waukegan, IL, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) is a progressive condition with chronic inflammation and joint destruction impacting quality of life.1 Dactylitis and enthesitis are clinically relevant domains…
Abstract Number: 0055 • ACR Convergence 2022
Protective Role for Mast Cells in TNF-induced Inflammatory-Erosive Arthritis and Its Associated Lymphatic Dysfunction in Mice
Yue Peng¹, H. Mark Kenney², Karen Bentley³, Lianping Xing⁴, Christopher Ritchlin⁵ and Edward Schwarz¹, ¹University of Rochester Medical Center, Rochester, NY, ²University of Rochester Medical Center, Henrietta, NY, ³University of Rochester, Rochester, ⁴University of Rochester Medical Center, Webster, NY, ⁵Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY
Background/Purpose: Inflammatory-erosive arthritis is exacerbated by lymphatic dysfunction (1). Mast cells (MCs) regulate lymphatic vessels by releasing inflammatory and vasoactive mediators (e.g. histamine) (2). Previous…
Abstract Number: 0548 • ACR Convergence 2022
Postural Orthostatic Tachycardia Syndrome, Small Fiber Neuropathy, and Systemic Inflammation: Are They Related?
Elizabeth Bettini, Carolyn Ramwell, Sangeeta Sule and Jeffery Moak, Children's National Hospital, Washington, DC
Background/Purpose: Postural Orthostatic Tachycardia Syndrome (POTS) is a dysautonomia associated with chronic autonomic and neuropathic symptoms, including pain in multiple body regions, paresthesia, fatigue, brain…
Abstract Number: 0659 • ACR Convergence 2022
Comprehensive Proteomic Screen of Murine Lupus Serum and Cerebrospinal Fluid Uncovers Diagnostic and Therapeutic Targets
Joshua Reynolds¹, Chandra Mohan², Yaxi Li² and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²University of Houston, Houston, TX
Background/Purpose: Up to 50% of SLE patients experience neuropsychiatric involvement (neuropsychiatric lupus, or NPLSE) through an unknown mechanism. Diagnosis currently relies on clinical criteria and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].